


DOCKET NO.: UNGR-1520



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger, DeKang Shen
and Guanli Wu

Serial No.: 09/218,660

Group Art Unit: 1616


Filing Date: December 22, 1998

Examiner: Not Yet Assigned

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE

Date of deposit: 3/16/99

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.


Typed Name: David A. Cherry
Registration No.: 35,099

Assistant Commissioner for Patents
Washington DC 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant wishes to call to the Examiner's attention the fact that reexaminations have been initiated in commonly owned patents Unger, U.S. Patent No. 5,527,521 and Unger, U.S. Patent No. 5,547,656. The status of each of these reexaminations is that Patentee has responded to a first Office Action mailed on April 10, 1998.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

Date: 3/16/89



Signature

David A. Cherry

Registration No. 35,099

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100

DOCKET NO.: UNGR-1520



PATENT

08/16/16
4/2/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 23 1999

MAILBOX-CUSTOMER
SERVICE CENTER

In Re Application of:

Evan C. Unger, DeKang Shen
and Guanli Wu

Serial No.: 09/218,660

Group Art Unit: 1616

Filing Date: December 22, 1998

Examiner: Not Yet Assigned

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE

Date of deposit: 3/16/99
I hereby certify that this paper is being deposited with the United
States Postal Service as First Class Mail, postage prepaid on the
date indicated above and is addressed to the Assistant
Commissioner for Patents, Washington, DC 20231.

Typed Name: David A. Cherry
Registration No.: 35,099

Assistant Commissioner for Patents
Washington DC 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$240.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$240.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☒ In view of the voluminous nature of references AC-AE, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.


- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: 3/16/99


David A. Cherry
Registration No. 35,099

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

DOCKET NO.: UNGR-1520

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger, DeKang Shen
and Guanli Wu



Serial No.: 09/218,660

Group Art Unit: 1616

Filing Date: December 22, 1998

Examiner: Not Yet Assigned

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND
THERAPEUTIC USE

Date of deposit: 3/16/99

I Hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Typed Name: David A. Cherry
Registration No.: 35,099

Assistant Commissioner for Patents
Washington DC 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$240.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$240.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☒ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

☒ Copies of references **AA-DD, FU-KR, and KT-LC** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. **08/497,684**, filed **June 7, 1995**; copies of references **DE-EO, EU-FT, KS, LD-NY, OE-OO, OT-PD, PI-PY, and RF-RL** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. **08/660,032**, filed **June 6, 1996**.


☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

English language abstracts were provided for those listed references which are not in the English language.

Date: **3/16/99**


David A. Cherry
Registration No. 35,099

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439